Market Overview

UPDATE: Credit Suisse Initiates Sunesis Pharmaceuticals at Outperform Ahead of Phase II Data

Related SNSS
Morning Market Gainers
Sunesis Pharma Offers New Data from VALOR Trial for Vosaroxin in Oilder Patients with Acute Myeloid Leukemia
Sunesis Pharma continues its clawback as it fine-tunes study results; shares up 9% (Seeking Alpha)

Credit Suisse initiated coverage on Sunesis Pharmaceuticals, Inc. (NASDAQ: SNSS) with an Outperform rating and a $7.00 price target.

Credit Suisse commented, "SNSS is a binary risk stock for which upside potential and probability of success are not fully reflected in the current share price. In part, we believe this is because the Phase III read out for vosaroxin is not expected until early 2014. However, we believe that shares could move significantly higher ahead of the event. Investors with binary risk tolerance should consider owning SNSS through the VALOR results. SNSS owns global rights to vosaroxin (owes a midteen royalty), so positive results would put SNSS on a path to commercial profitability or a potential premium acquisition."

Sunesis Pharmaceuticals closed at $4.00 on Monday.

Latest Ratings for SNSS

Jun 2015Roth CapitalMaintainsBuy
Jan 2015BTIG ResearchInitiates Coverage onBuy
Dec 2014Roth CapitalUpgradesNeutralBuy

View More Analyst Ratings for SNSS
View the Latest Analyst Ratings

Posted-In: Credit SuisseAnalyst Color Initiation Intraday Update Analyst Ratings


Related Articles (SNSS)

Around the Web, We're Loving...

Get Benzinga's Newsletters